Cargando…

60. Evaluation of Outcomes Associated with Intermittent Versus Extended Infusion of Piperacillin/tazobactam in Acutely Ill Veterans

BACKGROUND: Antibiotic dosing optimization is a key principle of antimicrobial stewardship. This study evaluated the impact of an extended infusion piperacillin/tazobactam dosing protocol on clinical outcomes in acutely ill veterans treated for infections at VA San Diego. METHODS: This retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Encarnacion, Marianne Angeli, Ma, Ariel, Johns, Scott T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776173/ http://dx.doi.org/10.1093/ofid/ofaa439.105

Ejemplares similares

1306. Comparison of the Use of Extended and Intermittent Infusion Cefepime and Piperacillin/tazobactam in Non-critically Ill, Obese Patients
por: Marg, Carolyn, et al.
Publicado: (2020)

Extended infusion of piperacillin–tazobactam versus intermittent infusion in critically ill egyptian patients: a cost-effectiveness study
por: Naiim, Christina Medhat, et al.
Publicado: (2022)

Piperacillin/tazobactam administered by continuous or intermittent infusion for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2009)

2805. Extended-Infusion versus Intermittent-Infusion Piperacillin/tazobactam for High Minimum Inhibitory Concentration Pseudomonas aeruginosa Infections
por: Shifko, Carlee R, et al.
Publicado: (2023)

2432. Appropriateness of Empiric Extended-Infusion Piperacillin/Tazobactam in the Intensive Care Unit
por: Tucker, Kendall, et al.
Publicado: (2018)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin/Tazobactam: Are Extended Infusions to Blame?
por: Navalkele, Bhagyashri, et al.
Publicado: (2015)

2687. Extended Infusions of Piperacillin/Tazobactam vs. Cefepime for Empiric Treatment of Neutropenic Fever
por: Norman, Sarah, et al.
Publicado: (2019)

212. Acute Kidney Injury with Piperacillin-tazobactam versus Cefepime in Combination with Vancomycin
por: Nguyen, Phuong Khanh, et al.
Publicado: (2020)

80. Pharmacoeconomic Analysis Comparing the Empiric Utilization of Cefepime Versus Piperacillin/tazobactam
por: Olmack, Kelsey, et al.
Publicado: (2020)

Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial
por: Bao, H., et al.
Publicado: (2016)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

2244. Clinical Outcomes with Extended Infusion (EI) vs. Intermittent Infusion (II) of Cefepime (FEP), Piperacillin/Tazobactam (TZP), and Meropenem (MEM) in Patients with Gram-Negative (GN) Bacteremia
por: Tran, Kieu-Nhi, et al.
Publicado: (2019)

Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
por: Felton, T W, et al.
Publicado: (2014)

Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients—A Multicenter Propensity Matched Analysis
por: Gonçalves-Pereira, João, et al.
Publicado: (2012)

Pharmacokinetic/pharmacodynamic predictions and clinical outcomes of patients with augmented renal clearance and Pseudomonas aeruginosa bacteremia and/or pneumonia treated with extended infusion cefepime versus extended infusion piperacillin/tazobactam
por: Gerlach, Anthony T., et al.
Publicado: (2019)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

Continuous versus intermittent administration of piperacillin–tazobactam in intensive care unit patients with ventilator-associated pneumonia
por: Fahimi, Fanak, et al.
Publicado: (2012)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock()
por: Sun, Yang, et al.
Publicado: (2023)

Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in Pseudomonas aeruginosa
por: Felton, T. W., et al.
Publicado: (2013)

Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever
por: Maarbjerg, Sabine F., et al.
Publicado: (2021)

Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn
por: Selig, Daniel J., et al.
Publicado: (2022)

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
por: Carlier, Mieke, et al.
Publicado: (2013)

Implementation of an Extended-Infusion Piperacillin-Tazobactam Dosing Protocol: Unexpected Findings when Monitoring Safety and Compliance with Smart Pump Technology
por: J. Rhodes, Nathaniel, et al.
Publicado: (2019)

220. Effectiveness of Piperacillin/tazobactam Loading Dose for Extended Infusion Dosing Among Patients with Gram-negative Bacteremia (EZ-LD)
por: Patel, Savan, et al.
Publicado: (2023)

Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study
por: Hyun, Dong-gon, et al.
Publicado: (2022)

Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
por: Ng, Tat Ming, et al.
Publicado: (2016)

P08 The quality of life and cost benefits of domiciliary 24-hour piperacillin/tazobactam 13.5 g infusion in patients with necrotizing otitis externa
por: Sacranie, Y., et al.
Publicado: (2022)

We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
por: Cotta, Menino Osbert, et al.
Publicado: (2016)

An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

Enterobacter endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
por: Singh, Trehan Hemant, et al.
Publicado: (2007)

Piperacillin-tazobactam-induced hypokalemia and metabolic alkalosis
por: Zaki, Syed Ahmed, et al.
Publicado: (2011)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017)

Piperacillin/tazobactam: Eosinophilic-pneumonia: case report
Publicado: (2021)

1282. Ceftolozane/Tazobactam Use in Critically Ill Patients Receiving Intermittent or Continuous Renal Replacement Therapy
por: Henry, Molly, et al.
Publicado: (2021)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

248. Why so Much Vancomycin and Piperacillin/Tazobactam Usage Given Known Risks of Nephrotoxicity
por: Son, Andrea, et al.
Publicado: (2020)

Correction to: An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

232. Impact of Weekend Initiation of Vancomycin or Piperacillin/Tazobactam on Days of Therapy Received upon Hospital Admission
por: McGregor, Jessina C, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4fhfevrldq5knebs1pifk5pmn7